Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3 C3G is an ultra-rare kidney disease typically diagnosed in young adults and often...
Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) )
Also on site :
- Trump says reconciliation with Musk is possible in interview before Tesla boss’s apology
- What we know about aid queue killings in Gaza
- US condemns multi-nation sanctions on far-right Israeli ministers